By Fineline Cube 
Shionogi Co., Ltd. (TYO: 4507) announced that its U.S. subsidiary, Shionogi Inc., has been awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield for Fetroja (cefiderocol), a critical countermeasure against high-priority Gram-negative bacterial biothreats. The agreement includes initial funding of USD 119 million, with multi-year options potentially reaching USD 482 million.
Contract Milestone
| Item | Detail |
|---|---|
| Awarding Agency | BARDA (U.S. Department of Health and Human Services) |
| Program | Project BioShield |
| Drug | Fetroja (cefiderocol) – IV antibiotic |
| Initial Funding | USD 119 million |
| Potential Total Value | Up to USD 482 million |
| Key Objectives | U.S. manufacturing site establishment, expanded use against biothreat pathogens (Burkholderia pseudomallei, Yersinia pestis), pediatric sNDA for HABP/VABP |
Drug Profile & Regulatory Status
- Mechanism: Siderophore cephalosporin that exploits bacterial iron-uptake systems to penetrate Gram-negative outer membranes
- Current FDA Approvals: Hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated urinary tract infections (cUTI)
- Global Approvals: Japan, European Union, and China for carbapenem-resistant and multidrug-resistant Gram-negative infections
- Biothreat Relevance: Active against WHO Priority 1 pathogens including Burkholderia pseudomallei (melioidosis) and Yersinia pestis (plague)
Strategic Impact
- U.S. Manufacturing: Contract funds establishment of a domestic drug formulation facility, enhancing supply chain security
- Pediatric Expansion: Supplemental New Drug Application (sNDA) to extend Fetroja’s use to children with HABP/VABP
- National Security: Positions Fetroja as a cornerstone of the U.S. medical countermeasure stockpile against antimicrobial resistance threats
- Commercial Outlook: Strengthens Shionogi’s anti-infectives portfolio; potential for additional government procurement globally
Forward-Looking Statements
This brief contains forward-looking statements regarding contract execution, regulatory submissions, and commercial expectations. Actual outcomes may vary due to manufacturing, regulatory, or funding uncertainties.-Fineline Info & Tech